Articles Related to gestational age
Macrocystis of the Lung in a Preterm Neonate: Case Report
Thoracic ultrasonography has been used to evaluate pulmonary parenchyma and the macrocystis of the lung in a preterm with congenital cystic adenomatoid malformation type I. The images gained have been important for diagnosis and therapeutic strategies in our case. An infant was prematurely born with congenital cystic adenomatoid malformation type I. The chest X-ray and computerized tomography showed a great opaque area in the entire right lung, we considered performing a pneumonectomy. This opaque area hampered the expansion of left lung. After draining the macrocystis by ultrasonography-guided puncture, it was possible considering and performing the lobectomy due to the reduction of the volume of macrocystis. During follow up at 4 months, the infant did not show complications and the chest X-ray revealed the reduction of volume of the dense area in parenchyma of right lung.
Inflammatory Myofibroblastic Tumor of Proximal Urethra in a Pregnant Female: A Unique Case Report
Inflammatory Myofibroblastic tumour (IMT) is a rare spindle tumour that mimics malignant processes. It can affect any part of the body, but rarely occurs in the genitourinary tract. We report a case of urethral IMT in a 31-year-old pregnant female of 18 weeks gestational age.
Descriptive Study of Exposure to Inhalation Zanamivir and Pregnancy-Related Outcomes
The Health Improvement Network (THIN) provided data from UK General Practitioners (GPs) for 144 pregnant women who were prescribed zanamivir and 144 age- and date-matched untreated comparators with no recorded diagnosis of influenza. Groups were assessed for baseline characteristics, treatment-emergent diagnoses in the mother, pregnancy outcomes and congenital malformations diagnosed in the offspring within 28 days of birth.
Pharmacy Compounding Quality Control and Pharmaceutical Development Strategies for Seventeen alpha Hydroxyprogesterone Caproate in Prevention of Preterm Delivery
Seventeen alpha hydroxyprogesterone caproate (17-OHPC) is the only FDA-approved drug labeled for prevention of preterm delivery. This drug is also available as a compounded product from licensed compounding pharmacies. This article reviews the FDA approval history and pharmacy compounding quality control data of 17-OHPC, as well as briefly discusses possible future pharmaceutical development strategies for 17-OHPC.